Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by 1832 Asset Management L.P.

1832 Asset Management L.P. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,806 shares of the biopharmaceutical company’s stock after acquiring an additional 552 shares during the period. 1832 Asset Management L.P.’s holdings in Regeneron Pharmaceuticals were worth $2,701,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in REGN. West Paces Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the last quarter. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $37,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on REGN. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Piper Sandler lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Argus lifted their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,074.95.

Regeneron Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:REGN traded up $14.44 during midday trading on Friday, reaching $1,078.63. The company had a trading volume of 380,897 shares, compared to its average volume of 386,591. The stock has a market capitalization of $118.85 billion, a P/E ratio of 31.86, a PEG ratio of 2.19 and a beta of 0.13. The stock’s fifty day moving average price is $1,033.85 and its 200-day moving average price is $977.31. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. Regeneron Pharmaceuticals, Inc. has a one year low of $723.56 and a one year high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the transaction, the chief executive officer now owns 466,877 shares in the company, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. Insiders have sold 65,074 shares of company stock valued at $64,546,123 over the last three months. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.